← Back to blog

What Is End-of-Life Care Like for Advanced Peritoneal Mesothelioma?

By CRYSTAL BAI •

What Is End-of-Life Care Like for Advanced Peritoneal Mesothelioma?

The short answer: Peritoneal mesothelioma is a rare cancer of the abdominal lining related to asbestos exposure. Unlike pleural mesothelioma, many peritoneal patients achieve prolonged survival with CRS/HIPEC surgery. In advanced or treatment-resistant disease, palliative care manages ascites, bowel complications, abdominal pain, and nutritional decline — with specialized expertise needed given the rarity.

Understanding Peritoneal Mesothelioma

Peritoneal mesothelioma — malignant mesothelioma of the peritoneum (abdominal lining) — is caused by prior asbestos exposure in most cases, with a long latency period of 20-40 years. It represents approximately 20-30% of all mesothelioma cases, with pleural mesothelioma being more common.

Unlike pleural mesothelioma, peritoneal mesothelioma has seen significant improvement in outcomes with cytoreductive surgery and HIPEC (heated intraperitoneal chemotherapy). Selected patients with low peritoneal cancer index (PCI) and good performance status can achieve median survival of 3-7 years or longer. However, not all patients are surgical candidates, and recurrence occurs.

When Peritoneal Mesothelioma Becomes Advanced

In unresectable or recurrent peritoneal mesothelioma, the symptom pattern is dominated by peritoneal disease:

  • Malignant ascites: Abdominal fluid accumulation causing massive distension, pressure, breathlessness, early satiety, and mobility impairment
  • Bowel obstruction: Tumor and adhesions cause single or multiple level obstructions
  • Pain: Visceral abdominal pain from tumor burden
  • Nutritional failure: Inability to eat adequately due to ascites pressure and bowel dysfunction
  • Fatigue: Progressive weakness as disease advances
  • Liver and other organ involvement: In advanced disease

Palliative Management

  • Ascites management: Serial paracentesis (may be weekly or more frequent); peritoneal drainage catheter (PleurX or similar) for home drainage; drainage of malignant peritoneal effusion provides significant symptomatic relief even when it cannot be curative
  • Bowel obstruction: Medical management with octreotide, steroids, antiemetics; venting gastrostomy; surgical bypass rarely indicated in advanced disease
  • Pain management: Multi-modal visceral pain management
  • Nutritional support: Comfort eating; TPN rarely beneficial in end-stage disease

Many peritoneal mesothelioma patients are eligible for legal compensation from asbestos trust funds or litigation — given the clear occupational exposure history. These funds can support end-of-life care costs. The Mesothelioma Applied Research Foundation (curemeso.org) and ADAO (Asbestos Disease Awareness Organization) provide patient resources and attorney referrals.

Frequently Asked Questions

What is the prognosis for peritoneal mesothelioma?

Prognosis varies significantly by whether patients receive CRS/HIPEC. Patients who undergo successful cytoreductive surgery with HIPEC can achieve median survival of 3-7+ years. Patients who are not surgical candidates have a much shorter prognosis — typically 6-12 months with systemic chemotherapy alone. Individual prognosis depends on disease burden, histology (epithelioid is better), and performance status.

Is CRS/HIPEC still possible with recurrent peritoneal mesothelioma?

Second and sometimes third CRS/HIPEC procedures are performed at specialized centers for carefully selected patients with recurrent peritoneal mesothelioma. The Peritoneal Surface Oncology Group International (PSOGI) has established criteria for repeat procedures. This should be evaluated at a high-volume center with extensive mesothelioma CRS/HIPEC experience.

How is massive ascites managed in peritoneal mesothelioma?

Malignant ascites in peritoneal mesothelioma is typically managed with paracentesis — draining fluid by needle. For patients requiring frequent drainage (every 1-2 weeks), tunneled drainage catheters (PleurX, Aspira) allow home drainage, dramatically reducing hospital visits and improving quality of life. Unlike fluid in other cancers, peritoneal mesothelioma ascites can sometimes be relatively thin and flows well through catheters.

Can immunotherapy help peritoneal mesothelioma?

Nivolumab plus ipilimumab was approved for pleural mesothelioma (CheckMate-743), and there is growing use in peritoneal mesothelioma though data is less mature. Clinical trials specifically for peritoneal mesothelioma with immunotherapy are ongoing. Major mesothelioma centers are the best place to explore this option.

Mesothelioma patients typically have legal recourse through: asbestos trust fund claims (over $30 billion in total trust assets), personal injury lawsuits against asbestos manufacturers, or VA benefits for veterans with asbestos exposure in military service. Mesothelioma specialized attorneys (often working on contingency) can evaluate eligibility rapidly. The Mesothelioma Applied Research Foundation provides attorney referrals.

Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.